Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 857-863

  Hoshimoto, Sojun ^a   Ueda, Masakazu ^a   Jinno, Hiromitsu ^a   Kitajima, Masaki ^a   Futami, Junichiro ^b   Seno, Masaharu ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

EGF receptor; Internalization; Ribonuclease; Targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; RIBONUCLEASE;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION;

AMINO ACID SEQUENCE; CARCINOMA, SMALL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; ESCHERICHIA COLI; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; LUNG NEOPLASMS; MICROSCOPY, FLUORESCENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RIBONUCLEASE, PANCREATIC; VULVAR NEOPLASMS;

EID: 33645825444     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ozawa S, Ueda M, Ando N, Shimizu N and Abe O: Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169-2173, 1989.
2. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402, 1987.
3. Veale D, Kerr N, Gibson GJ, Kelly PJ and Harris AL: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68: 162-165, 1993.
4. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A and Mancuso S: Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361-366, 1995.
5. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
6. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
7. Baselga J and Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60: 33-40, 2000.
8. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529, 1983.
9. Brinkmann U and Pastan I: Immunotoxins against cancer. Biochim Biophys Acta 1198: 27-45, 1994.
10. Hirota N, Ueda M, Ozawa S, Abe O and Shimizu N: Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 49: 7106-7109, 1989.
11. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW and Vitetta ES: Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 206: 227-234, 1993.
12. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW, Longo DL, Gould B, Frankel A, McClay EF, Howell S, Reed E, Willingham MC, FitzGerald DJ and Pastan I: Clinical evaluation of intraperitoneal pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9: 2095-2103, 1991.
13. Rybak SM, Sexena SK, Ackerman EJ and Youle RJ: Cytotoxic potential of ribonuclease hybrid proteins. J Biol Chem 266: 21202-21207, 1991.
14. Jinno H, Ueda M, Ozawa S, Kikuchi K, Ikeda T, Enomoto K and Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines - a trial for less immunogenic chimeric toxin. Cancer Chem Pharm 38: 303-308, 1996.
15. Laccetti P, Portella G, Mastronicola MR, Russo A, Piccoli R, D'Alessio G and Vecchio G: In vivo and in vitro growth-inhibitory effect of bovine seminal ribonuclease on a system of rat thyroid epithelial transformed cells and tumors. Cancer Res 52: 4582-4586, 1992.
16. Wu YN, Mikulski SM, Ardelt W, Rybak SM and Youle RJ: A cytotoxic ribonuclease. J Biol Chem 268: 10686-10693, 1993.
17. Saxena SK, Rybak SM, Winkler G, Meade HM, McGray P, Youle RJ and Ackerman EJ: Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem 266: 21208-21214, 1991.
18. Jinno H, Ueda M, Ozawa S, Ikeda T, Enomoto K, Psarras K, Kitajima M, Yamada H and Seno M: Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase1. Life Sci 58: 1901-1908, 1996.
19. Psarras K, Ueda M, Yamamura T, Ozawa S, Kitajima M, Aiso S, Komatsu S and Seno M: Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. Protein Eng 11: 1285-1292, 1998.
20. Futami J, Seno M, Kosaka M, Tada H, Seno S and Yamada H: Recombinant human pancreatic ribonuclease produced in E. coli: importance of the amino-terminal sequence. Biochem Biophys Res Commun 216: 406-413, 1995.
21. Futami J, Seno M, Ueda M, Tada H and Yamada H: Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Eng 12: 1013-1019, 1999
22. Futami J, Nukui E, Maeda T, Kosaka M, Tada H, Seno M and Yamada H: Optimum modification for the highest cytotoxicity of cationized ribonuclease. J Biochem 132: 223-228, 2002
23. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M and Yamada H: Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 40: 7518-7524, 2001.
24. Carpentier JL, White MF, Orci L and Kahn RC: Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells. J Cell Biol 105: 2751-2762, 1987.
25. Hopkins CR, Gibson A, Shipman M and Miller K: Movement of internalized ligand-receptor complexes along a continuous endosomal reticulum. Nature 346: 335-339, 1990.
26. Lee FS and Vallee BL: Structure and action of mammalian ribonuclease (angiogenin) inhibitor. Prog Nucleic Acid Res Mol Biol 44: 1-30, 1993.
27. Haigis MC, Kurten EL and Raines RT: Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 31: 1024-1032, 2003.
28. Monti DM and D'Alessio G: Cytosolic RNase inhibitor only affects RNases with intrinsic cytotoxicity. J Biol Chem 279: 39195-39198, 2004.
29. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandier A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefetinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290: 2149-2158, 2003.
30. Reynolds NA and Wagstaff AJ: Cetuximab in the treatment of metastatic colorectal cancer. Drugs 64: 109-118, 2004.
31. Janmaat ML, Kruyt FAE, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.